Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Reinisch, Walter"" wg kryterium: Autor


Tytuł :
Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab (SHP647) for the treatment of ulcerative colitis: the open-label study TURANDOT II.
Autorzy :
Reinisch W; Medical University of Vienna, Vienna, Austria.
Sandborn WJ; University of California San Diego, La Jolla, CA, USA.
Danese S; Humanitas University, Milan, Italy.
Hébuterne X; University of Nice Sophia Antipolis, CHU of Nice, Nice, France.
Kłopocka M; Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.
Tarabar D; Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia.
Vaňásek T; Charles University Hospital, Hradec Králové, Czech Republic.
Greguš M; Gastroenterology Centre, Nitra, Slovakia.
Hellstern PA; Nature Coast Clinical Research, Inverness, FL, USA.
Kim JS; Seoul National University College of Medicine, Seoul, South Korea.
Sparrow MP; Alfred Hospital, Melbourne, VIC, Australia.
Gorelick KJ; Zymo Consulting Group, Newtown Square, PA, USA.
Hoy M; Shire, a Takeda company, Lexington, MA, USA.
Goetsch M; Shire, a Takeda company, Zug, Switzerland.
Bliss C; Shire, a Takeda company, Lexington, MA, USA.
Gupta C; Cytel Inc, Cambridge, MA, USA.
Cataldi F; Shire, a Takeda company, Lexington, MA, USA.
Vermeire S; University Hospitals Leuven, Leuven, Belgium.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2021 Feb 18. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Passive Smoking Increases the Risk for Intestinal Surgeries in Patients With Crohn's Disease.
Autorzy :
Scharrer S; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Department of Gastroenterology and Endoscopy, University Hospital 'Dr. José E. González,' Monterrey, Mexico.
Lissner D; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine with Endoscopy, St. Joseph Hospital Berlin-Tempelhof, Berlin, Germany.
Primas C; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Novacek G; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Reinisch S; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Papay P; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine, Hospital Baden, Baden, Austria.
Dejaco C; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Vogelsang H; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Miehsler W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine, Hospital Brothers of St. John of God Salzburg, Salzburg, Austria.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Feb 16; Vol. 27 (3), pp. 379-385.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab.
Autorzy :
Panés J; Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Lindsay JO; The Royal London, Barts Health NHS Trust, London, United Kingdom.
Teich N; Internistische Gemeinschaftspraxis, Leipzig, Germany.; Faculty of Medicine, Jena University, Jena, Germany.
Lindgren S; Lund University, Malmo, Sweden.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Flynn HA; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Huyck S; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Yao R; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Philip G; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Reinisch W; Universitätsklinik für Innere Medizin III, Vienna, Austria.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Feb 12. Date of Electronic Publication: 2021 Feb 12.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism.
Autorzy :
Scharrer S; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Primas C; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Eichinger S; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Tonko S; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Praxis am rhy AG, Kriessern, Switzerland.
Kutschera M; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Koch R; Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.
Blesl A; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Mayer A; Department of Internal Medicine II, Universitätsklinikum St. Pölten, St. Pölten, Austria.
Haas T; Darmpraxis, Salzburg, Austria.
Feichtenschlager T; Department of Internal Medicine IV, Hospital Rudolfstiftung, Vienna, Austria.
Fuchssteiner H; Department of Internal Medicine IV, Hospital Elisabethinen Linz, Linz, Austria.
Steiner P; Department of Internal Medicine I, Hospital Wels-Grieskirchen, Wels, Austria.
Ludwiczek O; Department of Internal Medicine, Hospital Hall, Tyrol, Austria.
Platzer R; Department of Internal Medicine I, Hospital Wiener Neustadt, Wiener Neustadt, Austria.
Miehsler W; Department of Internal Medicine, Hospital Brothers of St. John of God Salzburg, Salzburg, Austria.
Tillinger W; Department of Internal Medicine, Franziskus Hospital, Vienna, Austria.
Apostol S; Department of Internal Medicine, Hietzing Clinic, Vienna, Austria.
Schmid A; Department of Internal Medicine 2, Danube Hospital, Vienna, Austria.
Schweiger K; Department of Internal Medicine 4, Ottakring Clinic, Vienna, Austria.
Vogelsang H; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Dejaco C; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Herkner H; Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
Novacek G; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Jan 02. Date of Electronic Publication: 2021 Jan 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.
Autorzy :
Reinisch W; Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Gecse K; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Halfvarson J; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Irving PM; Department of Gastroenterology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Jahnsen J; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
Peyrin-Biroulet L; Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.
Rogler G; Department of Gastroenterology and Hepatology, University Hospital, University of Zurich, Zurich, Switzerland.
Schreiber S; Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.; Clinic of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Danese S; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Jan 01; Vol. 27 (1), pp. 106-122.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
Autorzy :
Winthrop KL; Oregon Health & Science University, Portland , OR,  USA.
Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester , MN,  USA.
Baumgart DC; Division of Gastroenterology, University of Alberta, Edmonton , AB,  Canada.
Reinisch W; Medical University of Vienna , Vienna,  Austria.
Nduaka CI; Pfizer Inc, Collegeville , PA,  USA.
Lawendy N; Pfizer Inc, Collegeville , PA,  USA.
Chan G; Pfizer Inc, Collegeville , PA,  USA.
Mundayat R; Pfizer Inc, New York , NY,  USA.
Friedman GS; Pfizer Inc, Collegeville , PA,  USA.
Salese L; Pfizer Inc, Collegeville , PA,  USA.
Thorpe AJ; Pfizer Inc, Collegeville , PA,  USA.
Su C; Pfizer Inc, Collegeville , PA,  USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Nov 27. Date of Electronic Publication: 2020 Nov 27.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
End of Induction Patient Reported Outcomes Predict Clinical Remission but not Endoscopic Remission in Crohn's Disease.
Autorzy :
Wong ECL; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Buffone E; McGill University, Montreal, QC, Canada.
Lee SJ; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel, Vienna, Austria.
Narula N; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Nov 27. Date of Electronic Publication: 2020 Nov 27.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic.
Autorzy :
Reinisch W; Department of Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Danese S; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center- IRCCS-, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Peyrin-Biroulet L; Inserm NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, Lorraine University, France.
Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Oct 21; Vol. 14 (Supplement_3), pp. S815-S819.
Typ publikacji :
Journal Article; Practice Guideline
MeSH Terms :
Betacoronavirus*
Anti-Inflammatory Agents/*therapeutic use
Clinical Trials as Topic/*standards
Coronavirus Infections/*prevention & control
Gastrointestinal Agents/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Research Design/*standards
COVID-19 ; Clinical Trials as Topic/methods ; Coronavirus Infections/complications ; Global Health ; Humans ; Infection Control/methods ; Infection Control/standards ; Inflammatory Bowel Diseases/complications ; Pneumonia, Viral/complications ; Risk Management/methods ; Risk Management/standards ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic.
Autorzy :
Reinisch W; Department of Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Danese S; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center- IRCCS-, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Peyrin-Biroulet L; Inserm NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, Lorraine University, France.
Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Oct 21; Vol. 14 (Supplement_3), pp. S820.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
Autorzy :
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Panaccione R; Inflammatory Bowel Disease Unit, Department of Medicine, University of Calgary, AB, Canada.
Bossuyt P; Imelda General Hospital, Bonheiden, Belgium.
Baert F; AZ Delta, Roeselare-Menen, Belgium.
Armuzzi A; Presidio Columbus, Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Hébuterne X; Inflammatory Bowel Disease Center, University of Nice-Sophia Antipolis, CHU of Nice, Nice, France.
Travis S; Translational Gastroenterology Unit, National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
Danese S; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Sandborn WJ; Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Schreiber S; Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Berg S; Global Medical Affairs, AbbVie AB, Solna, Sweden.
Zhou Q; AbbVie Inc., North Chicago, IL, USA.
Kligys K; AbbVie Inc., North Chicago, IL, USA.
Neimark E; Research and Development, Gastroenterology/Immunology, AbbVie Inc., Worcester, MA, USA.
Suleiman AA; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
D'Haens G; Academic Medical Center, Amsterdam, Netherlands.
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Sep 18; Vol. 26 (10), pp. 1562-1571.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Week 6 Calprotectin Best Predicts Likelihood of Long-Term Endoscopic Healing in Crohn's Disease: A Post-Hoc Analysis of the UNITI/IM-UNITI Trials.
Autorzy :
Narula N; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Wong ECL; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Colombel JF; Division of Gastroenterology; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, WähringerGürtel, Vienna, Austria.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Sep 15. Date of Electronic Publication: 2020 Sep 15.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial.
Autorzy :
Wong ECL; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Marshall JK; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Narula N; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Aug 19. Date of Electronic Publication: 2020 Aug 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.
Autorzy :
Lewis JD; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Rutgeerts P; Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Feagan BG; Department of Medicine, University of Western Ontario, London, Ontario, Canada.
D'haens G; Academic Medical Center, Amsterdam, the Netherlands.
Danese S; Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mt Sinai, New York, New York, USA.
Reinisch W; Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Rubin DT; University of Chicago Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
Selinger C; Leeds Gastroenterology Institute, St James University Hospital, Leeds, United Kingdom.
Bewtra M; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Barcomb L; AbbVie Inc., North Chicago, Illinois, USA.
Lacerda AP; AbbVie Inc., North Chicago, Illinois, USA.
Wallace K; AbbVie Inc., North Chicago, Illinois, USA.
Butler JW; AbbVie Inc., North Chicago, Illinois, USA.
Wu M; AbbVie Inc., North Chicago, Illinois, USA.
Zhou Q; AbbVie Inc., North Chicago, Illinois, USA.
Liao X; AbbVie Inc., North Chicago, Illinois, USA.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Jan 06; Vol. 26 (2), pp. 304-313.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Abdominal Pain/*diagnosis
Anti-Inflammatory Agents/*therapeutic use
Constipation/*diagnosis
Crohn Disease/*drug therapy
Diarrhea/*diagnosis
Endoscopy, Gastrointestinal/*methods
Abdominal Pain/chemically induced ; Adult ; Clinical Trials as Topic ; Constipation/chemically induced ; Crohn Disease/pathology ; Diarrhea/chemically induced ; Drug Monitoring ; Endpoint Determination/standards ; Female ; Follow-Up Studies ; Humans ; Intestinal Mucosa/drug effects ; Male ; Prognosis ; Research Design ; Wound Healing/drug effects
Czasopismo naukowe
Tytuł :
Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy.
Autorzy :
Panés J; Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Lindsay JO; Department of Gastrointestinal and Liver Services, Royal London Hospital, Barts Health NHS Trust, London, UK.
Teich N; Innere Medizin/Gastroenterologie, Internistische Gemeinschaftspraxis, Leipzig, Germany.
Lindgren S; Department of Gastroenterology, Lund University, Malmo, Sweden.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cornillie F; Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
Flynn HA; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Huyck S; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Stryszak P; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Yao R; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Philip G; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Universitätsklinik für Innere Medizin III, Vienna, Austria.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1148-1157.
Typ publikacji :
Comparative Study; Journal Article; Observational Study
MeSH Terms :
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Adrenal Cortex Hormones/therapeutic use ; Adult ; Europe ; Female ; Gastrointestinal Agents/adverse effects ; Humans ; Immunosuppressive Agents/therapeutic use ; Infections/chemically induced ; Infliximab/adverse effects ; Male ; Product Surveillance, Postmarketing ; Prospective Studies ; Registries
Czasopismo naukowe
Tytuł :
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials.
Autorzy :
Hanauer S; Northwestern University, Digestive Health Centre, Chicago, IL, USA.
Sandborn WJ; University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA.
Colombel JF; Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, NY, USA.
Vermeire S; University Hospital Leuven, Gastroenterology, Leuven, Belgium.
Petersson J; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Kligys K; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Zhou Q; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Lazar A; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Reinisch W; Medical University of Vienna, Department for Gastroenterology and Hepatology, Vienna, Austria.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1227-1233.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Colitis, Ulcerative/*drug therapy
Adult ; Aged ; Biomarkers/blood ; Blood Proteins/analysis ; C-Reactive Protein/analysis ; Colitis, Ulcerative/pathology ; Erythrocyte Count ; Female ; Hematocrit ; Hemoglobins/analysis ; Humans ; Intestinal Mucosa/pathology ; Male ; Middle Aged ; Platelet Count ; Quality of Life ; Serum Albumin/analysis ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
Autorzy :
Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Reinisch W; Department of Internal Medicine III, Division Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria.
Panaccione R; Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Berg S; AbbVie AB, Solna, Sweden.
Alperovich G; AbbVie Spain S.L.U., Madrid, Spain.
Bereswill M; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Kalabic J; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Petersson J; AbbVie Inc., North Chicago, Illinois, USA.
Thakkar R; AbbVie Inc., North Chicago, Illinois, USA.
Robinson AM; AbbVie Inc., North Chicago, Illinois, USA.
D'Haens G; Academic Medical Center, Amsterdam, Netherlands.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2019 Aug 20; Vol. 25 (9), pp. 1522-1531.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Crohn Disease/*drug therapy
Registries/*statistics & numerical data
Adult ; Crohn Disease/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Response to Letter by Moulton et al.
Autorzy :
Narula N; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Pinto-Sanchez MI; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Calo NC; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Ford AC; Leeds Gastroenterology Institute, St. James's University Hospital, and Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.
Bercik P; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Reinisch W; Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Moayyedi P; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2019 Jul 17; Vol. 25 (8), pp. e99.
Typ publikacji :
Letter; Comment
MeSH Terms :
Depressive Disorder*
Inflammatory Bowel Diseases*
Anxiety ; Anxiety Disorders ; Depression ; Humans
Opinia redakcyjna
Tytuł :
Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease.
Autorzy :
Narula N; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Pinto-Sanchez MI; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Calo NC; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Ford AC; Leeds Gastroenterology Institute, St. James's University Hospital, and Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
Bercik P; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Reinisch W; Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Moayyedi P; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2019 Jun 18; Vol. 25 (7), pp. 1255-1261.
Typ publikacji :
Journal Article
MeSH Terms :
Quality of Life*
Severity of Illness Index*
Anxiety Disorders/*diagnosis
Depressive Disorder/*diagnosis
Hospitalization/*statistics & numerical data
Inflammatory Bowel Diseases/*complications
Adult ; Anxiety Disorders/etiology ; Anxiety Disorders/psychology ; Comorbidity ; Depressive Disorder/etiology ; Depressive Disorder/psychology ; Female ; Follow-Up Studies ; Humans ; Longitudinal Studies ; Male ; Prognosis ; Prospective Studies ; Psychiatric Status Rating Scales ; Risk Factors ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
Autorzy :
Reinisch W; Medical University of Vienna, Vienna, Austria.
Bressler B; University of British Columbia, Vancouver, Canada.
Curtis R; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Parikh A; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Yang H; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Rosario M; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Røseth A; Lovisenberg Diaconal Hospital, Oslo, Norway.
Danese S; Istituto Clinico Humanitas, Milan, Italy.
Feagan B; Robarts Clinical Trials, Robarts Research Institute, and the University of Western Ontario, London, Ontario, Canada.
Sands BE; Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Ginsburg P; Frank H Netter MD School of Medicine, Quinnipiac University, Hamden, Connecticut, USA.
Dassopoulos T; Baylor College of Medicine, Houston, Texas, USA.
Lewis J; Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Xu J; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Wyant T; Curis, Inc., Lexington, Massachusetts, USA.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2019 Mar 14; Vol. 25 (4), pp. 803-810.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Biomarkers/*metabolism
Colitis, Ulcerative/*drug therapy
Colitis, Ulcerative/*metabolism
Feces/*chemistry
Gastrointestinal Agents/*therapeutic use
Leukocyte L1 Antigen Complex/*metabolism
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; Colitis, Ulcerative/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prognosis ; ROC Curve ; Remission Induction ; Young Adult
Czasopismo naukowe
Tytuł :
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.
Autorzy :
Reinisch W; Medical University of Vienna, Vienna, Austria.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Gibson PR; Alfred Hospital and Monash Hospital, Melbourne, Australia.
Rutgeerts P; University Hospital Gasthuisberg, Leuven, Belgium.
Sandborn WJ; University of California-San Diego, La Jolla, California, USA.
Tarabar D; Military Medical Academy, Belgrade, Serbia.
Huyck S; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Khalifa A; MSD Switzerland, Luzern, Switzerland.
Marano C; Janssen R&D, LLC, Spring House, Pennyslvania, USA.
Philip G; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Yao R; Merck & Co., Inc., Kenilworth, New Jersey, USA.
Zhang H; Janssen R&D, LLC, Spring House, Pennyslvania, USA.
Cornillie F; MSD Switzerland, Luzern, Switzerland.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2019 Jan 01; Vol. 25 (1), pp. 163-171.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Quality of Life*
Severity of Illness Index*
Antibodies, Monoclonal/*therapeutic use
Colitis, Ulcerative/*drug therapy
Double-Blind Method ; Follow-Up Studies ; Humans ; Remission Induction ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies